The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease.

[1]  J. Frohlich,et al.  Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography , 2011, Journal of Lipid Research.

[2]  D. Rader,et al.  Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function[S] , 2011, Journal of Lipid Research.

[3]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[4]  L. Rochette,et al.  The free oxygen radicals test (FORT) to assess circulating oxidative stress in patients with acute myocardial infarction. , 2010, Atherosclerosis.

[5]  E. Duchene,et al.  Postprandial lipemia enhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia[S] , 2010, Journal of Lipid Research.

[6]  M. Taskinen,et al.  Effect of HDL composition and particle size on the resistance of HDL to the oxidation , 2010, Lipids in Health and Disease.

[7]  Vincent J Carey,et al.  Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. , 2010, The American journal of cardiology.

[8]  Man-ping Wu,et al.  Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the plasma HDL inflammatory index. , 2010, Cytokine.

[9]  H. Paulus,et al.  Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[10]  L. Correia,et al.  HDL-cholesterol level provides additional prognosis in acute coronary syndromes. , 2009, International journal of cardiology.

[11]  H. Moradi,et al.  In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. , 2009, Kidney international.

[12]  A. Waring,et al.  A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids , 2009, Journal of Lipid Research.

[13]  Alberto Piazza,et al.  Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants , 2009, Nature Genetics.

[14]  Adrian Hernandez,et al.  Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. , 2009, American heart journal.

[15]  Varghese George,et al.  Can dysfunctional HDL explain high coronary artery disease risk in South Asians? , 2008, International journal of cardiology.

[16]  Subramaniam Pennathur,et al.  Combined Statin and Niacin Therapy Remodels the High-Density Lipoprotein Proteome , 2008, Circulation.

[17]  D. Rader,et al.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. , 2008, Journal of the American College of Cardiology.

[18]  D. Rader,et al.  The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. , 2008, Journal of the American College of Cardiology.

[19]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[20]  D. Sviridov,et al.  Antiatherogenic functionality of high density lipoprotein: how much versus how good. , 2008, Journal of atherosclerosis and thrombosis.

[21]  A. Nègre-Salvayre,et al.  Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. , 2008, Atherosclerosis.

[22]  G. Franceschini,et al.  Anti-Inflammatory and Cardioprotective Activities of Synthetic High-Density Lipoprotein Containing Apolipoprotein A-I Mimetic Peptides , 2008, Journal of Pharmacology and Experimental Therapeutics.

[23]  K. Kalantar-Zadeh,et al.  HDL-inflammatory index correlates with poor outcome in hemodialysis patients. , 2007, Kidney international.

[24]  M. Reilly,et al.  CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. , 2007, Journal of the American College of Cardiology.

[25]  D. Rader.  Molecular regulation of HDL metabolism and function: implications for novel therapies. , 2006, The Journal of clinical investigation.

[26]  H. Brewer,et al.  Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. , 2006, The American journal of cardiology.

[27]  K. Kalunian,et al.  Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[28]  S. Cuzzocrea,et al.  Oxidative stress as the leading cause of acute myocardial infarction in diabetics. , 2006, Cardiovascular drug reviews.

[29]  B. Lam,et al.  HDL dysfunction in obstructive sleep apnea. , 2006, Atherosclerosis.

[30]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[31]  D. Gordon,et al.  High-Density Lipoprotein Cholesterol and Cardiovascular Disease , 2005 .

[32]  Philippe Giral,et al.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. , 2004, The Journal of clinical endocrinology and metabolism.

[33]  D. Johns,et al.  Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. , 2004, Clinical chemistry.

[34]  A. Tall,et al.  A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly Published, JLR Papers in Press, February 16, 2004. DOI 10.1194/jlr.M300520-JLR200 , 2004, Journal of Lipid Research.

[35]  Shirin Rahmani,et al.  Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.

[36]  J. Frohlich,et al.  Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. , 2003, Clinical chemistry.

[37]  M. Hayden,et al.  Restoration of Endothelial Function by Increasing High‐Density Lipoprotein in Subjects With Isolated Low High‐Density Lipoprotein , 2003, Circulation.

[38]  F. Ruschitzka,et al.  High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.

[39]  J. Frohlich,et al.  The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). , 2001, Clinical biochemistry.

[40]  S. Reddy,et al.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. , 2001, Journal of lipid research.

[41]  G. Franceschini,et al.  Cardiovascular Status of Carriers of the Apolipoprotein A-IMilano Mutant: The Limone sul Garda Study , 2001, Circulation.

[42]  I. Crandall,et al.  Characterization of peroxynitrite-oxidized low density lipoprotein binding to human CD36. , 2001, Atherosclerosis.

[43]  G. Jensen,et al.  Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. , 2000, Circulation.

[44]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[45]  J. Frohlich,et al.  Fractional Esterification Rate of HDL Particles in Patients With Type 2 Diabetes: Relation to coronary heart disease risk factors , 1998, Diabetes Care.

[46]  J. Frohlich,et al.  Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[47]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.